In addition, recent evidence that inhibition of PI3KC2β improves insulin sensitivity and glucose homeostasis[18], reverses the myopathy seen in mice mutant for myotubulin related protein 1 (MTM1)[29], and slows tumor growth[30] suggests that pharmacologic inhibitors of PI3KC2β may be beneficial in multiple different disease beyond their effects on mast cells. Here, MTM1 is linked to neoplasm.